These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 526012)

  • 1. Hydrolysis of cefamandole nafate in dialysis patients.
    Nielsen RL; Wolen R; Luft FC; Ozawa T
    Antimicrob Agents Chemother; 1979 Nov; 16(5):683-5. PubMed ID: 526012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrolysis of cefamandole nafate to cefamandole in vivo.
    Wold JS; Joost RR; Black HR; Griffith RS
    J Infect Dis; 1978 May; 137 Suppl():S17-S24. PubMed ID: 650001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefamandole in patients undergoing hemodialysis.
    Campillo JA; Lanao JM; Dominguez-Gil A; Tabernero JM; Rubio F
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):416-20. PubMed ID: 500264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.
    Ahern MJ; Finkelstein FO; Andriole VT
    Antimicrob Agents Chemother; 1976 Sep; 10(3):457-61. PubMed ID: 984787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delineation of the relative antibacterial activity of cefamandole and cefamandole nafate.
    Turner JR; Preston DA; Wold JS
    Antimicrob Agents Chemother; 1977 Jul; 12(1):67-72. PubMed ID: 18988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.
    Appel GB; Neu HC; Parry MF; Goldberger MJ; Jacob GB
    Antimicrob Agents Chemother; 1976 Oct; 10(4):623-5. PubMed ID: 984799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefamandole kinetics during cardiopulmonary bypass.
    Polk RE; Archer GL; Lower R
    Clin Pharmacol Ther; 1978 Apr; 23(4):473-80. PubMed ID: 630796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of cefamandole nafate and cefoxitin sodium solutions.
    Das Gupta V; Stewart KR
    Am J Hosp Pharm; 1981 Jun; 38(6):875-9. PubMed ID: 7246563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formylation of glucose by cefamandole nafate at alkaline pH.
    Indelicato JM; Stewart BA; Engel GL
    J Pharm Sci; 1980 Oct; 69(10):1183-8. PubMed ID: 7420288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefamandole nafate to cefamandole by microbiological assay.
    Winely CL; Spears JC; Scott JK
    Antimicrob Agents Chemother; 1979 Sep; 16(3):424-6. PubMed ID: 41479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cefamandole nafate on the toxicity of tobramycin.
    Wold JS; Turnipseed SA; Broddle WD; Owen NV
    Antimicrob Agents Chemother; 1977 Oct; 12(4):465-9. PubMed ID: 921240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of cefamandole nafate to cefamandole sodium.
    Indelicato JM; Wilham WL; Cerimele BJ
    J Pharm Sci; 1976 Aug; 65(8):1175-8. PubMed ID: 10412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and pain study of cefamandole nafate.
    Foster TS; Shrewsbury RP; Coonrod JD
    J Clin Pharmacol; 1980; 20(8-9):526-33. PubMed ID: 7000857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of cefamandole and cefamandole nafate in human plasma and urine by high-performance liquid chromatography with column switching.
    Lee HS; Zee OP; Kwon KI
    J Chromatogr; 1990 Jun; 528(2):425-33. PubMed ID: 2384580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
    Hess JR; Berman SJ; Boughton WH; Sugihara JG; Musgrave JE; Wong EG; Siemsen AM
    Antimicrob Agents Chemother; 1980 Feb; 17(2):251-3. PubMed ID: 7387145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicologic evaluation of cefamandole nafate in laboratory animals.
    Wold JS; Welles JS; Owen NV; Gibson WR; Morton DM
    J Infect Dis; 1978 May; 137 Suppl():S51-S59. PubMed ID: 650004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefamandole nafate therapy in the treatment of acute urinary tract infections.
    Short HD; Gentry LO; Sessoms S
    J Antimicrob Chemother; 1976 Dec; 2(4):345-50. PubMed ID: 802125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.